CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2.
Angiotensin-Converting Enzyme 2
/ genetics
Animals
Antibodies, Neutralizing
/ blood
Antibodies, Viral
/ blood
COVID-19
/ prevention & control
COVID-19 Vaccines
/ immunology
Cell Line
Chlorocebus aethiops
Genome, Viral
/ genetics
Humans
Mice
Mice, Transgenic
SARS-CoV-2
/ genetics
Spike Glycoprotein, Coronavirus
/ immunology
Vero Cells
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
30 06 2021
30 06 2021
Historique:
received:
02
04
2021
accepted:
14
06
2021
entrez:
1
7
2021
pubmed:
2
7
2021
medline:
15
7
2021
Statut:
epublish
Résumé
The ongoing SARS-CoV-2 pandemic necessitates the fast development of vaccines. Recently, viral mutants termed variants of concern (VOC) which may escape host immunity have emerged. The efficacy of spike encoding mRNA vaccines (CVnCoV and CV2CoV) against the ancestral strain and the VOC B.1.351 was tested in a K18-hACE2 transgenic mouse model. Naive mice and mice immunized with a formalin-inactivated SARS-CoV-2 preparation were used as controls. mRNA-immunized mice develop elevated SARS-CoV-2 RBD-specific antibody and neutralization titers which are readily detectable, but significantly reduced against VOC B.1.351. The mRNA vaccines fully protect from disease and mortality caused by either viral strain. SARS-CoV-2 remains undetected in swabs, lung, or brain in these groups. Despite lower neutralizing antibody titers compared to the ancestral strain BavPat1, CVnCoV and CV2CoV show complete disease protection against the novel VOC B.1.351 in our studies.
Identifiants
pubmed: 34193869
doi: 10.1038/s41467-021-24339-7
pii: 10.1038/s41467-021-24339-7
pmc: PMC8245475
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
ACE2 protein, human
EC 3.4.17.23
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4048Subventions
Organisme : Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research)
ID : 01KI20703
Références
Nat Med. 2021 Apr;27(4):622-625
pubmed: 33654292
Nat Med. 2021 Apr;27(4):620-621
pubmed: 33558724
Cell Host Microbe. 2021 Mar 10;29(3):477-488.e4
pubmed: 33535027
Nature. 2021 Feb;590(7847):630-634
pubmed: 33276369
Mol Phylogenet Evol. 2021 Apr;157:107017
pubmed: 33242581
Nat Rev Microbiol. 2021 Mar;19(3):141-154
pubmed: 33024307
Nature. 2020 Oct;586(7830):516-527
pubmed: 32967006
Nat Med. 2021 Mar;27(3):440-446
pubmed: 33531709
Signal Transduct Target Ther. 2020 Oct 13;5(1):237
pubmed: 33051445
Cell Rep Med. 2021 Feb 16;2(2):100204
pubmed: 33521695
Nature. 2021 May;593(7857):136-141
pubmed: 33706364
Nat Immunol. 2020 Nov;21(11):1327-1335
pubmed: 32839612
Cell. 2021 Apr 29;184(9):2372-2383.e9
pubmed: 33743213
Sci Immunol. 2021 Mar 4;6(57):
pubmed: 33664060
Nature. 2021 May;593(7857):142-146
pubmed: 33780970
Nature. 2020 Oct;586(7830):509-515
pubmed: 32967005
Cell. 2021 Jan 21;184(2):476-488.e11
pubmed: 33412089
Sci Transl Med. 2021 Jan 27;13(578):
pubmed: 33431511
Transbound Emerg Dis. 2020 Nov 15;:
pubmed: 33191578
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
Science. 2021 Mar 12;371(6534):1152-1153
pubmed: 33514629
Nat Commun. 2020 Nov 30;11(1):6122
pubmed: 33257679
Nature. 2021 Apr;592(7852):122-127
pubmed: 33636719
Nat Commun. 2020 Nov 27;11(1):6059
pubmed: 33247099
NPJ Vaccines. 2021 Apr 16;6(1):57
pubmed: 33863911
Lancet. 2021 Feb 6;397(10273):452-455
pubmed: 33515491
Cell. 2021 Apr 29;184(9):2348-2361.e6
pubmed: 33730597
Sci Rep. 2018 Aug 30;8(1):13108
pubmed: 30166611
EBioMedicine. 2021 Jun;68:103403
pubmed: 34049240
N Engl J Med. 2021 Mar 17;384(15):1468-1470
pubmed: 33730471
N Engl J Med. 2021 May 20;384(20):1885-1898
pubmed: 33725432
Science. 2020 Dec 18;370(6523):1464-1468
pubmed: 33184236